2025
SJR Q2
JCR Q2 · 4,3
OA
ESCI
Journal detail
Australian Prescriber
- Publisher
- Therapeutic Guidelines Ltd
- Country
- Australia · Pacific Region
- Type
- journal
- ISSN
-
0312800818393942
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,687
- Quartile Q2
- H-Index 50
- Cites/doc 1,49
- Docs (3y) 158
- Cites (3y) 235
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 4,3
- 5Y JIF 4,7
- JCI 0,9
WoS indexes
- ESCI
Subject classification
Categories (SJR)
- Pharmacology (medical) Q2
Areas
- Medicine
WoS categories
- Pharmacology & Pharmacy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 0,687 | 4,3 | 4,7 | 0,9 | Q2 | 50 |
| 2024 | Q2 | Q1 | 0,781 | 4,2 | 4,1 | 0,94 | Q2 | 45 |
| 2023 | Q2 | Q2 | 0,675 | 3,4 | 3,5 | 0,8 | Q2 | 45 |
| 2022 | Q2 | — | 0,624 | 2,7 | 3,5 | 0,71 | Q2 | 45 |
| 2021 | Q3 | — | 0,5 | — | — | 0,73 | Q2 | 45 |
| 2020 | Q2 | — | 0,735 | — | — | 0,89 | Q2 | 45 |
| 2019 | Q2 | — | 0,591 | — | — | — | — | 45 |
| 2017 | Q3 | — | 0,465 | — | — | — | — | 45 |
| 2016 | Q3 | — | 0,412 | — | — | — | — | 45 |
| 2015 | Q3 | — | 0,291 | — | — | — | — | 45 |
| 2014 | Q3 | — | 0,194 | — | — | — | — | 45 |
| 2013 | Q3 | Q4 | 0,169 | 0,4 | 0,4 | — | — | 45 |
| 2012 | Q3 | Q3 | 0,175 | 0,8 | — | — | — | 45 |
| 2011 | Q3 | Q3 | 0,168 | 0,5 | — | — | — | 45 |
| 2010 | Q3 | Q4 | 0,201 | 0,4 | — | — | — | 45 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | PHARMACOLOGY & PHARMACY | ESCI | Q2 | Q2 | 95/356 |
| 2024 | PHARMACOLOGY & PHARMACY | ESCI | Q1 | Q2 | 75/352 |
| 2023 | PHARMACOLOGY & PHARMACY | ESCI | Q2 | Q2 | 105/354 |
| 2022 | PHARMACOLOGY & PHARMACY | ESCI | — | Q2 | — |
| 2021 | PHARMACOLOGY & PHARMACY | ESCI | — | Q2 | — |
| 2020 | PHARMACOLOGY & PHARMACY | ESCI | — | Q2 | — |
| 2013 | MEDICINE, GENERAL & INTERNAL | SCIE | Q4 | — | 131/156 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 239/256 |
| 2012 | MEDICINE, GENERAL & INTERNAL | SCIE | Q3 | — | 95/155 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 218/261 |
| 2011 | MEDICINE, GENERAL & INTERNAL | SCIE | Q3 | — | 114/155 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 238/261 |
| 2010 | MEDICINE, GENERAL & INTERNAL | SCIE | Q4 | — | 117/153 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 233/252 |